Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations

Levine, Melvin D.; Barrington, David A. Mix; Hampel, Heather; Goodfellow, Paul J.; Cohn, David E.

doi:10.1016/j.ygyno.2022.07.016

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An analysis comparing standard upfront MGPT versus IHC for all newly diagnosed endometrial cancer demonstrated cost savings of $259 per patient. 32 In summary, evidence suggests that a population approach to testing would allow us to identify more at-risk patients and family members in a more equitable way that would decrease costs.…”

Section: Population Testing Outside the Setting Of A Specific Phenoty...mentioning

confidence: 99%

The Evolution of Genetic Testing from Focused Testing to Panel Testing and from Patient Focused to Population Testing: Are We There Yet?

Gima

Solomon

Hampel

2023

Clin Colon Rectal Surg

Self Cite

View full text Add to dashboard Cite

The field of cancer genetics has evolved significantly over the past 30 years. Genetic testing has become less expensive and more comprehensive which has changed practice patterns. It is no longer necessary to restrict testing to those with the highest likelihood of testing positive. In addition, we have learned that the criteria developed to determine who has the highest likelihood of testing positive are neither sensitive nor specific. As a result, the field is moving from testing only the highest risk patients identified based on testing criteria to testing all cancer patients. This requires new service delivery models where testing can be mainstreamed into oncology clinics and posttest genetic counseling can be provided to individuals who test positive and those with concerning personal or family histories who test negative. The use of videos, testing kiosks, chatbots, and genetic counseling assistants have been employed to help facilitate testing at a larger scale and have good patient uptake and satisfaction. While testing is important for cancer patients as it may impact their treatment, future cancer risks, and family member's cancer risks, it is unfortunate that their cancer could not be prevented in the first place. Population testing for all adults would be a strategy to identify individuals with adult-onset diseases before they develop cancer in an attempt to prevent it entirely. A few research studies (Healthy Nevada and MyCode) have offered population testing for the three Centers for Disease Control and Prevention Tier 1 conditions: hereditary breast and ovarian cancer syndrome, Lynch syndrome, and familial hypercholesterolemia finding a prevalence of 1 in 70 individuals in the general population. We anticipate that testing for all cancer patients and the general population will continue to increase over the next 20 years and the genetics community needs to help lead the way to ensure this happens in a responsible manner.

show abstract

Section: Population Testing Outside the Setting Of A Specific Phenoty...mentioning

confidence: 99%

The Evolution of Genetic Testing from Focused Testing to Panel Testing and from Patient Focused to Population Testing: Are We There Yet?

Gima

Solomon

Hampel

2023

Clin Colon Rectal Surg

Self Cite

View full text Add to dashboard Cite

show abstract

Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review

Mirza,

Goerke,

Anderson

et al. 2024

Value in Health

View full text Add to dashboard Cite

Differential Receipt of Genetic Services Among Patients With Gynecologic Cancer and Their Relatives: A Review of Challenges to Health Equity

Kanbergs,

Rauh-Hain,

Wilke

2024

Clinical Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Up to 14% of endometrial cancers and 23% of epithelial ovarian cancers are associated with genetic predispositions. Referral for genetic testing and counseling can significantly impact a patient’s oncologic outcomes. However, significant disparities in genetic referral and testing exist within medically underserved and minority populations in the United States. These disparities in care and access to care are multifactorial, often involving patient-level, health care-level, and system-level factors. In this review, we focus on disparities in genetic testing among patients with ovarian and uterine cancer, and the missed opportunities for primary cancer prevention among their relatives.

show abstract

Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations

Cited by 3 publications

References 30 publications

The Evolution of Genetic Testing from Focused Testing to Panel Testing and from Patient Focused to Population Testing: Are We There Yet?

The Evolution of Genetic Testing from Focused Testing to Panel Testing and from Patient Focused to Population Testing: Are We There Yet?

Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review

Differential Receipt of Genetic Services Among Patients With Gynecologic Cancer and Their Relatives: A Review of Challenges to Health Equity

Contact Info

Product

Resources

About